Literature DB >> 7861487

Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi.

S B Streem1.   

Abstract

A study was done to determine the long-term incidence and cause of recurrent stones following percutaneous nephrostolithotomy alone (13 patients) or combined with extracorporeal shock wave lithotripsy (31) for management of documented infection related struvite renal calculi. The patients were followed for 12 to 111 months (mean 41.7) to censorship or time of new stone formation. Of these patients 12 (27%) had recurrent stones at 12 to 61 months (mean 32.3) after treatment. As determined by a Kaplan-Meier estimate, the risk of new stone formation 5 years after treatment was 36.8%. Potential risk factors for recurrence, including history of stones, associated anatomical abnormalities, procedure used, radiographic status at completion of treatment and recurrent infection during followup, were analyzed with Cox's proportional hazards model. Of these potential risk factors, only an associated anatomical abnormality was found to influence significantly the rate of recurrent stone formation (p = 0.005). We conclude that continued surveillance for recurrent stones is mandatory even for patients initially rendered stone-free and those who maintain sterile urine. In addition, because the presence of a significant anatomical or functional urinary tract abnormality places a patient at much higher risk for recurrence, we suggest that subsequent studies be stratified as to the presence or absence of these abnormalities.

Entities:  

Mesh:

Year:  1995        PMID: 7861487     DOI: 10.1097/00005392-199503000-00005

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Aspects on how extracorporeal shockwave lithotripsy should be carried out in order to be maximally effective.

Authors:  Hans-Göran Tiselius; Christian G Chaussy
Journal:  Urol Res       Date:  2012-06-27

2.  Should metabolic evaluation be performed in patients with struvite stones?

Authors:  Muhammad Waqas Iqbal; Richard H Shin; Ramy F Youssef; Adam G Kaplan; Fernando J Cabrera; Jonathan Hanna; Charles D Scales; Michael N Ferrandino; Glenn M Preminger; Michael E Lipkin
Journal:  Urolithiasis       Date:  2016-05-30       Impact factor: 3.436

3.  PCNL MONOTHERAPY FOR RENAL CALCULI - AN INITIAL EXPERIENCE.

Authors:  Deepak Batura
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 4.  Stone formation and management after bariatric surgery.

Authors:  Sarah Tarplin; Vishnu Ganesan; Manoj Monga
Journal:  Nat Rev Urol       Date:  2015-04-07       Impact factor: 14.432

5.  Percutaneous nephrolithotomy in adult patients with spina bifida, severe spinal deformity and large renal stones.

Authors:  M Alsinnawi; W C Torreggiani; R Flynn; T E D McDermott; R Grainger; J A Thornhill
Journal:  Ir J Med Sci       Date:  2012-12-10       Impact factor: 1.568

6.  Evaluation of urinary abnormalities in urolithiasis patients: A study from North India.

Authors:  R Kumar; R Kapoor; B Mittal; A Kumar; R D Mittal
Journal:  Indian J Clin Biochem       Date:  2003-07

7.  Metabolic assessment in pure struvite stones formers: is it necessary?

Authors:  Alexandre Danilovic; Thiago Augusto Cunha Ferreira; Samirah Abreu Gomes; Isabela Akemi Wei; Fabio Carvalho Vicentini; Fabio Cesar Miranda Torricelli; Giovanni Scala Marchini; Eduardo Mazzucchi; Miguel Srougi; William Carlos Nahas
Journal:  J Bras Nefrol       Date:  2021 Apr-Jun

8.  Nephrolithiasis-induced end stage renal disease.

Authors:  M Ounissi; T Gargueh; M Mahfoudhi; K Boubaker; H Hedri; R Goucha; E Abderrahim; F Ben Hamida; T Ben Abdallah; F El Younsi; H Ben Maiz; A Kheder
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-03-11

9.  Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis.

Authors:  Kai Wang; Jing Ge; Wenlong Han; Dong Wang; Yinjuan Zhao; Yanhao Shen; Jiexun Chen; Dongming Chen; Jing Wu; Ning Shen; Shuai Zhu; Bin Xue; Xianlin Xu
Journal:  BMC Urol       Date:  2022-04-19       Impact factor: 2.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.